FDA-RFI-75F40125Q00020_Business Data Enrichment Services_QandA.xlsx
XLSX spreadsheet 18 KB Posted
- Attached to
- Business Data Enrichment Services
- Solicitation number
- FDA-RFI-75F40125Q00020
About this file
This document is a Question and Answer (Q&A) sheet related to a Request for Information (RFI) issued by the Food and Drug Administration (FDA) for Business Data Enrichment Services. The RFI seeks to obtain technical and/or business information and input from the marketplace regarding the availability of existing or potential solutions to implement an enterprise master data management program and improve the completeness and accuracy of the FDA's business data.
The key details include: The incumbent is Dun & Bradstreet, and the current contract information can be found on the Federal Procurement Data System - Next Generation (FPDS-NG). The FDA is open to considering set-asides for small businesses and other contract vehicles beyond the GSA Multiple Award Schedule. The FDA is interested in the ability to integrate with various third-party data enrichment platforms. Respondents are encouraged to include innovative approaches in their responses. The FDA is not conducting discussions at this time, but may contact vendors if additional information is required. This RFI does not commit the government to an award and all responses will become government property.
View the file
Other files
| File | Type | Posted |
|---|---|---|
| Attachment A - RFI Questionnaire.xlsx | XLSX spreadsheet | |
| FDA-RFI-75F40125Q00020 Business Data Enrichment Services.docx | DOCX document | |
| Appendix A - Enterprise Performance Life Cycle Framework.pdf | ||
| Attachment B - SOW_102424.docx | DOCX document |
On GovTribe
Work with this file
- Download the original file
- Contacts named in this file
- Similar government files
- Ask GovTribe AI about this file
Text version
Sheet1
| Questions from Industry | Government's Answers |
| Could you please share the incumbent details? | Dun & Bradstreet |
| Could you kindly confirm whether this initiative represents a new undertaking, or is there an incumbent currently delivering these services? | Dun & Bradstreet |
| If an incumbent exists, may we request the relevant details of their contract, including the contract number? | This is publically available on FPDS-NG. |
| Would you please provide us with an approximate timeline for the RFP release? | Any additional information released now would be premature |
| Are there any set-aside considerations for this opportunity? | Any additional information released now would be premature. |
| Could you share the anticipated contract value associated with this opportunity? | Any additional information released now would be premature |
| In each section of the response template, there is a question “How would you like to be evaluated for this task area?”. For clarification purposes, is this offering something along the lines of “Technical demonstration, oral presentation, in-person meeting” or is the FDA seeking clarification on specific evaluation criteria (Best Value, LPTA, etc.)? | Best Value |
| Is this the current work? If it is, what is the contract number? Who is the incumbent? What the value (i.e. Dollar amount) of the current contract? | Dun & Bradstreet is currently providing these services. The contract information can be readily found on FPDS-NG. It is too early in market research to estimate the dollar amount. |
| Would Government consider set-aside for small business? | Yes. If market research indicates there is at least two small businesses capable of performing the work as identified in the SOW. |
| Would government consider other contract vehicles other than GSA MAS for more accessible vehicles? | Yes. For the purposes of this RFI the FDA is exploring options and is open to contract vehicles other than GSA MAS. |
| Are there any specific third-party data enrichment platforms that the FDA prefers for integration, beyond those mentioned like GS1, LEI, and SAM.gov? | it is not preferrence, but ability to integrate with additional third party platforms with firms, product and economics data e.g. Moodys, S&P, Dun and Bradstreet, IQVIA, CIRCANA, social media services e.g. REDDIT |
| Should the response to Attachment A focus primarily on current capabilities, or can we include innovative approaches we plan to implement to meet FDA’s needs? | include innovative approaches the vendor plans to implement to meet FDA’s needs |
| Would it be possible to request a brief discussion to ensure our understanding of the specific goals within data validation and enrichment matches the FDA’s current strategic priorities? | The FDA is not conducting discussions at this time. If clarification is needed, the government will take that initiative. |
| Is the FDA going to have an Industry Day? | The FDA is exploring options at this time. Any addition information released now would be premature. |
File details come from the government source that posted it. Updated .